drugset / Trial / NCT06508749
The Tatelo Plus Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of HIV suppression in early-treated children.
Timeline
- Start
- 2024-11-11
- Primary completion
- 2027-09-03
- Completion
- 2028-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PGDM1400LS | Monoclonal antibody | — | Intravenous |
| Subject | PGT121.414.LS | Monoclonal antibody | — | Intravenous |
| Subject | VRC07-523LS | Monoclonal antibody | — | Intravenous |